These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 19268968)

  • 1. In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment.
    Reaven GM; Lieberman JA; Sethuraman G; Kraemer H; Davis JM; Blasey C; Tsuang MT; Schatzberg AF
    J Psychiatr Res; 2009 Jul; 43(11):997-1002. PubMed ID: 19268968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of ziprasidone and olanzapine on glucose and lipid metabolism in first-episode schizophrenia].
    Shao P; Ou J; Wu R; Fang M; Chen H; Xu Y; Zhao J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 38(4):365-9. PubMed ID: 23645236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine.
    Newcomer JW; Meyer JM; Baker RA; Eudicone JM; Pikalov A; Vester-Blokland E; McQuade RD; Crandall DT; Carson WH; Marcus RN; L'italien G
    Schizophr Res; 2008 Dec; 106(2-3):300-7. PubMed ID: 18973991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A twenty-four-week, open-label study on ziprasidone's efficacy and influence on glucolipid metabolism in patients with schizophrenia and metabolic disorder.
    Li CH; Shi L; Zhan GL; Rao SZ; Zhang H
    Eur Rev Med Pharmacol Sci; 2013 Aug; 17(16):2136-40. PubMed ID: 23893178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement in antipsychotic-related metabolic disturbances in patients with schizophrenia switched to ziprasidone.
    Montes JM; Rodriguez JL; Balbo E; Sopelana P; Martin E; Soto JA; Delgado JF; Diez T; Villardaga I
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):383-8. PubMed ID: 17129654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder.
    Simpson GM; Glick ID; Weiden PJ; Romano SJ; Siu CO
    Am J Psychiatry; 2004 Oct; 161(10):1837-47. PubMed ID: 15465981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ziprasidone as an adjuvant for clozapine- or olanzapine-associated medical morbidity in chronic schizophrenia.
    Henderson DC; Fan X; Copeland PM; Sharma B; Borba CP; Forstbauer SI; Miley K; Boxill R; Freudenreich O; Cather C; Evins AE; Goff DC
    Hum Psychopharmacol; 2009 Apr; 24(3):225-32. PubMed ID: 19283774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
    Kinon BJ; Basson BR; Gilmore JA; Tollefson GD
    J Clin Psychiatry; 2001 Feb; 62(2):92-100. PubMed ID: 11247108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of long-term metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder.
    Bobo WV; Bonaccorso S; Jayathilake K; Meltzer HY
    Psychiatry Res; 2011 Sep; 189(2):200-7. PubMed ID: 21802150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect on lipid profiles of switching from olanzapine to another second-generation antipsychotic agent in veterans with schizophrenia.
    Garman PM; Ried LD; Bengtson MA; Hsu C; McConkey JR
    J Am Pharm Assoc (2003); 2007; 47(3):373-8. PubMed ID: 17510032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of switching antipsychotic drug treatment to aripiprazole or ziprasidone for improving metabolic profile and atherogenic dyslipidemia: a 12-month, prospective, open-label study.
    Chen Y; Bobo WV; Watts K; Jayathilake K; Tang T; Meltzer HY
    J Psychopharmacol; 2012 Sep; 26(9):1201-10. PubMed ID: 22234928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of metabolic and prolactin variables from a six-month randomised trial of olanzapine and quetiapine in schizophrenia.
    Bushe C; Sniadecki J; Bradley AJ; Poole Hoffmann V
    J Psychopharmacol; 2010 Jul; 24(7):1001-9. PubMed ID: 19240085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ziprasidone's effect on metabolic markers in patients with diabetes and chronic schizophrenia.
    Lindenmayer JP; Tedeschi F; Yusim A; Khan A; Kaushik S; Smith RC; Parakadavil M
    Clin Schizophr Relat Psychoses; 2012 Jan; 5(4):185-92. PubMed ID: 22182455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in weight, plasma lipids, and glucose in adults treated with ziprasidone: a comprehensive analysis of pfizer-initiated clinical trials.
    Pappadopulos E; Newcomer JW; Kolluri S
    J Clin Psychiatry; 2012 Jun; 73(6):e742-8. PubMed ID: 22795213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of ziprasidone and olanzapine on body composition and metabolic parameters: an open-label comparative pilot study.
    Park S; Yi KK; Kim MS; Hong JP
    Behav Brain Funct; 2013 Jul; 9():27. PubMed ID: 23866300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone.
    Weiden PJ; Newcomer JW; Loebel AD; Yang R; Lebovitz HE
    Neuropsychopharmacology; 2008 Apr; 33(5):985-94. PubMed ID: 17637612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early changes of plasma lipids during treatment with atypical antipsychotics.
    Rettenbacher MA; Ebenbichler C; Hofer A; Kemmler G; Baumgartner S; Edlinger M; Hummer M; Lechleitner M; Fleischhacker WW
    Int Clin Psychopharmacol; 2006 Nov; 21(6):369-72. PubMed ID: 17012984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The apparent effects of ziprasidone on plasma lipids and glucose.
    Kingsbury SJ; Fayek M; Trufasiu D; Zada J; Simpson GM
    J Clin Psychiatry; 2001 May; 62(5):347-9. PubMed ID: 11411816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
    McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
    J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia.
    Breier A; Berg PH; Thakore JH; Naber D; Gattaz WF; Cavazzoni P; Walker DJ; Roychowdhury SM; Kane JM
    Am J Psychiatry; 2005 Oct; 162(10):1879-87. PubMed ID: 16199834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.